USP issues call for candidates for its 2015-2020 Council of Experts.
The U.S. Pharmacopeial Convention (USP) has announced its call for candidates for the 2015–2020 Council of Experts, USP’s scientific decision-making body.
USP’s Council of Experts is responsible for developing and revising standards that are included in USP’s seven compendia: The United States Pharmacopeia and the National Formulary; Medicines Compendium; USP on Compounding; Herbal Medicines Compendium; Dietary Supplements Compendium; and Food Chemicals Codex.
Currently more than 30% of the Council’s members comprise experts from outside of the US. The 2015–2020 Council of Experts includes 26 Expert Committees, six of which will meet outside of the US. All Expert Committees are supported by USP’s international site and Rockville, Maryland headquarters staff. The 2015–2020 Council of Experts will benefit from USP’s network of laboratories, which includes over 170,000 square feet of laboratory resources and a global staff located in the US, India, China, and Brazil.
The Council of Experts is elected every five years at the meeting of the USP Convention, with the next meeting to take place in April 2015. New experts will begin their five-year tenure on July 1, 2015. Members of the Council of Experts serve as chairs of USP’s Expert Committees, each of which addresses a specific standards-setting area within USP. Theseareas include chemical medicines, biologic medicines, excipients, compounded preparations, dietary supplements, and food ingredients. USP is also seeking candidates to serve as members of Expert Committees.
Candidates may nominate themselves or a colleague at http://uspgo.to/c
Source: USP
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.